Rubicon CEO Office
Product Opportunity ScreenerAbout this pageEvery R&D and product opportunity, scored 0–100 on how well it fits Rubicon. Use the filters and the weighting sliders to change what 'good' means to you; click any row to see the full scoring breakdown and the recommendation — Prioritize, Watchlist, or Reject.
Rank R&D and product opportunities by Rubicon-fit and R&D ROI · 10 flagged to prioritize
18 opportunities
| Product | Therapy | Dosage | Market | Comp. | R&D cost | Peak sales | Margin | ROI | Strategic | Rubicon-fit | Call | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quetiapine ER Tablets | CNS | Oral Solid | $980M | 1 | ₹56 cr | ₹145 cr | 71% | 60 | 90 | 80 | Prioritize | |
| Levetiracetam ER Sprinkle | CNS | Oral Solid | $480M | 0 | ₹26 cr | ₹76 cr | 69% | 71 | 88 | 78 | Prioritize | |
| Fluticasone-X Nasal Spray | Allergy | Nasal Spray | $410M | 1 | ₹24 cr | ₹72 cr | 62% | 65 | 86 | 75 | Prioritize | |
| Clonidine Oral Solution | CNS | Oral Liquid | $260M | 0 | ₹18 cr | ₹54 cr | 66% | 71 | 84 | 74 | Prioritize | |
| Risperidone Oral Solution | CNS | Oral Liquid | $240M | 0 | ₹15.5 cr | ₹45 cr | 71% | 74 | 86 | 74 | Prioritize | |
| Dexmedetomidine Oral Film | CNS | Oral Solid | $540M | 0 | ₹47 cr | ₹90 cr | 74% | 47 | 88 | 74 | Prioritize | |
| Budesonide Drug-Device Inhaler | Respiratory | Nasal Spray | $620M | 1 | ₹69 cr | ₹112 cr | 68% | 36 | 80 | 71 | Watchlist | |
| Amlodipine Oral Suspension | CVS | Oral Liquid | $205M | 0 | ₹14.5 cr | ₹41 cr | 63% | 66 | 80 | 71 | Prioritize | |
| Sumatriptan Nasal Spray | CNS | Nasal Spray | $290M | 1 | ₹22 cr | ₹52 cr | 65% | 54 | 84 | 71 | Prioritize | |
| Metoprolol Oral Suspension | CVS | Oral Liquid | $230M | 1 | ₹15 cr | ₹42 cr | 64% | 66 | 78 | 69 | Prioritize | |
| Mometasone MD Nasal Spray | Allergy | Nasal Spray | $300M | 1 | ₹35 cr | ₹56 cr | 66% | 38 | 80 | 65 | Prioritize | |
| Tacrolimus Topical Ointment | Dermatology | Topical | $160M | 1 | ₹12 cr | ₹29 cr | 61% | 55 | 72 | 62 | Watchlist | |
| Olopatadine MD Nasal Spray | Allergy | Nasal Spray | $340M | 2 | ₹38 cr | ₹60 cr | 60% | 34 | 76 | 62 | Watchlist | |
| Esmolol Injectable | CVS | Injectable | $430M | 1 | ₹52 cr | ₹70 cr | 69% | 30 | 64 | 61 | Watchlist | |
| Latanoprost Ophthalmic | Other | Ophthalmic | $210M | 1 | ₹30 cr | ₹36 cr | 67% | 29 | 62 | 57 | Watchlist | |
| Diclofenac Topical Gel | Other | Topical | $120M | 4 | ₹8 cr | ₹21 cr | 54% | 57 | 50 | 50 | Watchlist | |
| Generic SPF Lotion | Dermatology | Topical | $85M | 6 | ₹6 cr | ₹14 cr | 47% | 48 | 40 | 39 | Reject | |
| Pediatric Ibuprofen Suspension | Other | Oral Liquid | $70M | 8 | ₹4.5 cr | ₹11 cr | 44% | 48 | 36 | 39 | Reject |